People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ikena Oncology, Inc. | — | Biotechnology | Series C | $117.6M | $449.1M | 2023 |
Sergio Santillana at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sergio Santillana on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 1 | 17 |
| David Bonita | 1 | 6 |
| Iain Dukes | 1 | 5 |
| Otello Stampacchia | 1 | 4 |
| Owen Hughes | 1 | 4 |
| Jean-Francois D. Formela | 1 | 3 |
| Maria D. Koehler | 1 | 1 |
| Richard D. Wooster | 1 | 1 |
| Michelle Zhang | 1 | 1 |
| Iain D. Dukes | 1 | 1 |
| Otello D. Stampacchia | 1 | 1 |
| Richard Wooster | 1 | 1 |
| Jotin Marango | 1 | 1 |
| Mark Manfredi | 1 | 1 |
| Jeffrey Ecsedy | 1 | 1 |
| Maria Koehler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.